KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
21 hedge funds and large institutions have $2.63M invested in KalVista Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 13 closing their positions.
34% less funds holding
Funds holding: 32 → 21 (-11)
58% less capital invested
Capital invested by funds: $6.25M → $2.63M (-$3.62M)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$131K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$51.7K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.6K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.46K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$53 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.78M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$398K |
| 3 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$183K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$63.6K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
26
Paloma Partners
Greenwich,
Connecticut
| – | -$27K | -2,905 | Closed |
|
|
CS
27
Credit Suisse
Zurich,
Switzerland
| – | -$18K | -2,015 | Closed |
|
|
ARTA
28
A.R.T. Advisors
New York
| – | -$17K | -1,935 | Closed |
|
29
Citadel Advisors
Miami,
Florida
| – | -$18K | -1,923 | Closed |
|
|
SFA
30
Sequoia Financial Advisors
Akron,
Ohio
| – | -$10K | -1,071 | Closed |
|
|
TSS
31
Two Sigma Securities
New York
| – | -$10K | -1,066 | Closed |
|
32
Millennium Management
New York
| – | -$9K | -1,006 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$1.8K | -239 | -80% |
|
KALV Hedge Fund Activity: Q3 2016 in Review
21 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2016, worth a combined $2.63M — down 58% from $6.25M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KALV and 2 opened new positions — a net loss of 11 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $131K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $1.78M sold.
- 21 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2016, down from 32 in Q2 2016.
- Funds reported $2.63M of KalVista Pharmaceuticals stock for Q3 2016, down 58% quarter-over-quarter.
- 2 funds opened new KalVista Pharmaceuticals positions in Q3 2016 and 13 closed out, a net change of -11 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2016 was Renaissance Technologies, an estimated $131K added.
- The largest KalVista Pharmaceuticals seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2016.